Published in J Clin Psychiatry on November 01, 2007
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA (2014) 4.06
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study. Schizophr Bull (2009) 1.20
Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry (2009) 1.19
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry (2010) 1.16
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol (2014) 1.15
Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry (2008) 1.12
Schizophrenia: overview and treatment options. P T (2014) 1.06
Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am (2012) 1.04
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry (2013) 0.97
Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry (2014) 0.93
Clozapine: a distinct, poorly understood and under-used molecule. J Psychiatry Neurosci (2010) 0.91
Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag (2011) 0.90
Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am J Health Syst Pharm (2014) 0.88
Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther (2011) 0.87
Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl) (2013) 0.82
Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) (2012) 0.82
Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment. Community Ment Health J (2014) 0.79
Off-label use of sodium valproate for schizophrenia. PLoS One (2014) 0.78
Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison. Clin Psychopharmacol Neurosci (2015) 0.78
Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy. BMC Psychiatry (2013) 0.77
Second-generation antipsychotic discontinuation in first episode psychosis: an updated review. Clin Psychopharmacol Neurosci (2011) 0.77
A conditional model of evidence-based decision making. J Eval Clin Pract (2009) 0.76
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. Psychiatr Serv (2016) 0.75
Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities. Noro Psikiyatr Ars (2015) 0.75
Schizophrenia: current concepts and approaches to patient care. Am Health Drug Benefits (2008) 0.75
Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals. J Psychiatr Pract (2016) 0.75
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat (2016) 0.75
Effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia: a descriptive pre/post study. BMC Health Serv Res (2016) 0.75
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurol Ther (2016) 0.75
An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatr Dis Treat (2013) 0.75
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry (2017) 0.75
Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand. Clinicoecon Outcomes Res (2016) 0.75
The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia. Psychiatry Res (2013) 0.75
The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil. PLoS One (2015) 0.75
Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams. Ther Adv Psychopharmacol (2016) 0.75
Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. J Clin Psychopharmacol (2017) 0.75
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Adv Ther (2017) 0.75
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
The state of science and research in clinical pharmacy. Pharmacotherapy (2006) 7.26
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 4.58
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2003) 2.83
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Illness management and recovery: a review of the research. Psychiatr Serv (2002) 2.48
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
The brief negative symptom scale: psychometric properties. Schizophr Bull (2010) 2.27
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry (2007) 2.26
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. Br J Psychiatry (2006) 2.24
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry (2011) 2.15
Bipolar I disorder: psychopathology, medical management and dental implications. J Am Dent Assoc (2002) 2.15
The Hartford study of supported employment for persons with severe mental illness. J Consult Clin Psychol (2004) 2.12
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther (2004) 2.10
Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc (2003) 2.09
Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv (2007) 1.99
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv (2007) 1.93
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry (2011) 1.86
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry (2009) 1.82
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry (2004) 1.79
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry (2007) 1.78
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull (2006) 1.75
Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry (2004) 1.75
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull (2007) 1.72
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry (2009) 1.70
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res (2005) 1.69
Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull (2002) 1.68
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry (2002) 1.68
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry (2012) 1.67